Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Update on the PASADENA trial of prasinezumab for Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, Roche Pharma Research & Early Development, Basel, Switzerland, discusses the latest data from the PASADENA study (NCT03100149), focusing on the potential of prasinezumab to slow the progression of Parkinson’s disease. Prasinezumab, the first monoclonal antibody targeting aggregated alpha-synuclein, has shown promising results in its ability to bind the aggregated alpha-synuclein protein, which is thought to contribute to the progression of the disease. The three-year data from the study compared individuals treated with prasinezumab to a real-world population without any treatment. The findings support the hypothesis that prasinezumab may indeed slow the motor progression of Parkinson’s disease. Dr Pagano highlights the encouraging results from the first three years of the study and mentions an ongoing randomized control trial to further confirm these findings. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Pagano is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.